COMMUNIQUÉS West-GlobeNewswire

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
12/10/2026
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiting for [...]
ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
12/10/2026
PORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf [...]
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
12/10/2026
CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, [...]
Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
12/10/2026
CHEST-led panel to showcase data from the Phase 3 SynAIRgy and LunAIRo trials, exploring potential new paradigms for advancing OSA patient management CAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. ( [...]
PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026
12/10/2026
SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in [...]
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers
12/10/2026
CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports [...]
Broken Tooth in West Hollywood? Same-Day Extraction and Implant Placement May Be an Option for Qualifying Patients
12/10/2026
A 427-dentist study in the Journal of Dentistry found extraction recommendations rose from under 1% to about 52% as periodontal involvement went from mild to severe. Los Angeles Advanced Dentistry in West Hollywood [...]
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
12/10/2026
Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT) SAN CARLOS, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a [...]
LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026
12/10/2026
BURLINGTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after the market [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
12/10/2026
COPENHAGEN, Denmark, October 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Septembre 2026
12/10/2026
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Sanofi: Information concerning the total number of voting rights and shares – September 2026
12/10/2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
12/10/2026
Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP Late-breaking [...]
AB Science tiendra une web conférence le mercredi 14 octobre 2026 de 18h à 19h30
12/10/2026
COMMUNIQU É DE PRESSE AB SCIENCE TIENDRA UNE WEB CONFÉRENCE LE MERCREDI 14 OCTOBRE DE 18H A 19H30 Paris, 12 octobre 2026, 18h AB Science SA (Euronext - FR0010557264 - AB) tiendra une web conférence le mercredi 14 [...]
AB Science will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m.
12/10/2026
PRESS RELEASE AB SCIENCE WILL HOLD A WEB CONFERENCE ON WEDNESDAY, OCTOBER 14, FROM 6:00 P.M. TO 7:30 P.M. Paris, October 12, 2026, 6:00 p.m. AB Science SA (Euronext - FR0010557264 - AB) will hold a web conference on [...]
Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia
12/10/2026
Presentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with imetelstat FOSTER CITY, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Geron [...]
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
12/10/2026
Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 development Two presentations selected for [...]
NEXGEL Announces 1-for-20 Reverse Stock Split Effectiveness
12/10/2026
Split-adjusted trading to begin on The Nasdaq Capital Market at market open on October 12, 2026 LANGHORNE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a company with [...]

Pages